curcumin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases interleukin-6 concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6“Median IL-6 levels were markedly lower in the curcumin group than in the placebo group (5.50 [4.39–9.00] vs. 13.69 [11.27–15.65], p < 0.001), with a large effect size ( r = 0.78, 95% CI: 0.68–0.86).”
Quoted verbatim from Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Curcumin 1500 mg/day orally for 12 months
- Population
- Adults with type 2 diabetes mellitus and obesity (n=114 randomised); secondary endpoint; between-group comparison at 12 months
Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2026PMID:42123439Industry fundedPermalink
Keep reading
- Everything the graph holds on curcumin
- Every compound studied against Interleukin-6 concentration
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M0Q1MVJ3MSJ16JT6GWAYZBPY